CytomX Therapeutics (CTMX) Expected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $12.3880 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $10.26 million during the quarter, compared to the consensus estimate of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. On average, analysts expect CytomX Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

Shares of CTMX opened at $3.17 on Thursday. The firm has a market capitalization of $540.35 million, a P/E ratio of -7.74 and a beta of 2.08. CytomX Therapeutics has a 52 week low of $1.72 and a 52 week high of $8.21. The stock has a 50 day moving average price of $3.41 and a two-hundred day moving average price of $4.32.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares in the last quarter. Invesco Ltd. bought a new stake in CytomX Therapeutics during the second quarter worth $32,000. Goldman Sachs Group Inc. purchased a new position in CytomX Therapeutics in the first quarter worth $39,000. JPMorgan Chase & Co. boosted its position in CytomX Therapeutics by 5,648.0% in the third quarter. JPMorgan Chase & Co. now owns 16,152 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 15,871 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in CytomX Therapeutics in the 4th quarter valued at $52,000. 67.77% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CTMX. Wolfe Research assumed coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They set an “outperform” rating and a $6.00 target price on the stock. Wall Street Zen raised CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research upgraded CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. Finally, HC Wainwright cut their price objective on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $12.10.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.